Classification criteria and treatment modalities in primary Sjögren’s syndrome

References

• Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Intern Med 2004;64:1275-84
   Google Scholar
• Chehata S, Laatiri MA, Bouaouina N, et al. Gougerot-Sjögren’s syndrome disclosed by MALT lynphoma of the salivary glands. Report of 3 cases. Ann Med Interne (Paris) 2000;151:93-6
   PubMedGoogle Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome : a revised version of the European criteria proposed by the American and European Consensus Group. Ann Rheum Dis 2002;61:554-8
   PubMed Web of Science ®Google Scholar
• Gottenberg JE. Primary Sjögren’s syndrome : pathophysiological, clinical and therapeutic advances. Joint Bone Spine 2009;76(6):591-4
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE. Pathogenesis of Sjögren’s syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res 2012;64:475-87
   PubMed Web of Science ®Google Scholar
• Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009;68:1310-15
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised SICCA cohort. Ann Rheum Dis 2014;73(1):31-8
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Hagiwara S, Asashima H, et al. Validation of different sets of criteria for the diagnosis of Sjögren’s syndrome in Japanese patients. Mod Rheumatol 2013;23:219-25
   PubMed Web of Science ®Google Scholar
• Vitali C, Bootsma H, Bowman SJ, et al. Classification criteria for Sjögren’s syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013;72:476-8
   PubMed Web of Science ®Google Scholar
• Cornec D, Jousse-Joulin S, Pers JO, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjogren’s syndrome. Towards new diagnostic criteria? Arthritis Rheum 2013;65:216-25
   PubMed Web of Science ®Google Scholar
• Salaffi F, Carotti M, Iagnocco A, et al. Ultrasonography of salivary glands in primary Sjogren’s syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford) 2008;47:1244-9
   PubMed Web of Science ®Google Scholar
• Milic V, Petrovic R, Boricic I, et al. Ultrasonography of major salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria for primary Sjögren’s syndrome. Rheumatology (Oxford) 2012;51:1081-5
   PubMed Web of Science ®Google Scholar
• Vitali C, Palombi G, Baldini C, et al. Sjögren’s Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007;56:2223-31
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjögren’s Systemic Clinical Activity Index (SCAI)-a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology (Oxford) 2007;46:1845-51
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. Eular Sjögren’s syndrome disease activity index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren’s syndrome. Ann Rheum Dis 2010;69(6):1103-9
   PubMed Web of Science ®Google Scholar
• Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-6
   PubMed Web of Science ®Google Scholar
• Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 2007;144:86-92
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012;31:945-9
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009;54:321-38
   PubMed Web of Science ®Google Scholar
• Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. Efficacy assessment of Nutrilarm®, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome. J Fr Ophtalmol 2011;34:448-55
   PubMed Web of Science ®Google Scholar
• Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010;9:CD006775
   Google Scholar
• Rosenthal P, Cotter J. The Boston scleral lens in the management of severe ocular surface disease. Ophthalmol Clin North Am 2003;16:89-93
   PubMedGoogle Scholar
• Kruszka P, O’Brian RJ. Diagnosis and Management of Sjögren Syndrome. Am Fam Physician 2009;79:465-70
   PubMed Web of Science ®Google Scholar
• Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Intern Med 2004;164:1275-84
   PubMed Web of Science ®Google Scholar
• Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren’s syndrome. Arthritis Rheum 2000;43:1647-54
   PubMed Web of Science ®Google Scholar
• Dawson LJ, Fox PC, Smith PM. Sjogren’s syndrome-the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 2006;45:792-8
   PubMed Web of Science ®Google Scholar
• Brimhall J, Jhaveri MA, Yepes JF. Efficacy of cevimeline vs pilocarpine in the secretion of saliva: a pilot study. Spec Care Dentist 2013;33:123-7
   PubMedGoogle Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Peck AB. Unraveling the Pathophysiology of Sjogren Syndrome-Associated Dry Eye Disease. Ocul Surf 2009;7:11-27
   PubMed Web of Science ®Google Scholar
• Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren’s syndrome. J Rheumatol 1998;25(5):896-9
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome. Results of the randomized controlled trial of Remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome – a double blind, randomised clinical trial. PLoS ONE 2012;7(1):e30123
   PubMed Web of Science ®Google Scholar
• Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 2013;9(9):544-56
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8(5):e59868
   PubMed Web of Science ®Google Scholar
• Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52(5):360-4
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Puéchal X, et al. Inefficacy of hydroxychloroquine in primary sjögren’s syndrome: results at 12 months of the randomized placebo-controlled trial of plaquenil in primary sjögren’s syndrome. Presented at American College of Rheumatology Congress; 9 - 14 November 2012; Washington, DC, USA
   Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol 2008;67:185-92
   PubMed Web of Science ®Google Scholar
• Daridon C, Devauchelle V, Hutin P, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum 2007;56:1464-77
   PubMedGoogle Scholar
• Ittah M, Miceli-Richard C, Gottenberg JE, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome. Arthritis Res Ther 2006;8(2):R51
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38:1058-64
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 2003;62:168-71
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9(7):491-502
   PubMed Web of Science ®Google Scholar
• Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24(6):983-4
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 2013;52:276-81
   PubMed Web of Science ®Google Scholar
• Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65(6):796-803
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004
   PubMed Web of Science ®Google Scholar
• Mariette X, Quartuccio L, Seror R, et al. Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren’s Syndrome. Presented at American College of Rheumatology Congress; 9 - 14 November 2012; Washington, DC, USA
   Google Scholar
• Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren’s syndrome. Arthritis Res Ther 2011;13(5):R170
   PubMed Web of Science ®Google Scholar
• Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 2012;119(7):e43-50
   PubMed Web of Science ®Google Scholar
• Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234-44
   PubMed Web of Science ®Google Scholar
• Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmun 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Arai M, Jain S, Weaver AA, et al. Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood. J Transl Med 2010;8:51
   PubMed Web of Science ®Google Scholar
• Bolstad AI, Le Hellard S, Kristjansdottir G, et al. Association between genetic variants in the tumour necrosis factor/lymphotoxin α/lymphotoxin β locus and primary Sjogren’s syndrome in Scandinavian samples. Ann Rheum Dis 2012;71(6):981-8
   PubMed Web of Science ®Google Scholar
• Gatumu MK, Skarstein K, Papandile A, et al. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren’s syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009;11(1):R24
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67(11):1541-4
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Tolerance and EfficAcy of Rituximab in primary Sjögren Syndrome: results of the randomized controlled trial TEARS. Ann Intern Med 2014;160:233-42
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72(6):1026-31
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008;67:450-7
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012;125:327-36
   PubMed Web of Science ®Google Scholar
• Saraux A. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren’s syndrome. Autoimmun Rev 2010;9:609-14
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8(4):R129
   PubMed Web of Science ®Google Scholar
• Adler A, Koerner M, Foerger F. Histological, serological and clinical changes in response to Abatacept treatment of Sjögren syndrome. Presented at American College of Rheumatology Congress; 9 – 14 November 2012; Washington, DC, USA
   Google Scholar
• Meiners PM, Vissink A, Spijkervet FKl, et al. Abatacept reduces disease activity in early primary sjögren’s syndrome:one year results from a phase II open-label study. Presented at EULAR Congress; 12 – 15 June 2013; Madrid, Spain
   Google Scholar
• Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren’s syndrome. Gene Ther 2003;14:1605-18
   Web of Science ®Google Scholar
• Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren’s syndrome. Ann Rheum Dis 2006;6:195-200
   Google Scholar
• Vosters JL, Yin H, Roescher N, et al. Local expression of tumor necrosis factor-receptor 1: immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren’s syndrome. Arthritis Res Ther 2009;11(6):R189
   PubMed Web of Science ®Google Scholar
• Roescher N, Vosters JL, Al Saleh G, et al. Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren’s syndrome as a proof of concept. Mol Ther 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci USA 2012;109(47):19403-7
   PubMed Web of Science ®Google Scholar